Alkermes (ALKS) has been in focus after announcing extensive new data presentations across its psychiatry and sleep medicine franchises, along with the launch of a phase 2 trial for orexin 2 agonist ...
Source LinkAlkermes (ALKS) has been in focus after announcing extensive new data presentations across its psychiatry and sleep medicine franchises, along with the launch of a phase 2 trial for orexin 2 agonist ...
Source Link
Comments